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Abstract
Background: Effectiveness of colorectal cancer (CRC) screening with fecal immunochemical 
stool blood tests (FIT) requires high rates of colonoscopy follow up for abnormal FIT, and use of 
high quality tests. We characterized colonoscopy referral and completion among patients with 
abnormal FIT, and type of FIT implemented in a sample of Southern California Federally 
Qualified Health Centers (FQHCs).
Methods: FQHCs in San Diego, Imperial, and Los Angeles counties were invited to define a 
cohort of ≥150 consecutive abnormal FIT patients 2015–2016 and provide data on gender, 
insurance status, diagnostic colonoscopy referral and completion within six months of abnormal 
FIT, and type (brand) of FIT implemented. Primary outcomes were proportion with colonoscopy 
referral and completion for all patients at each FQHC and in aggregate.
Results: Eight FQHCs provided data for 1,229 patients with abnormal FIT; 46% were male and 
20% uninsured. Among abnormal FIT patients, 89% (n=1,091/1,229; 95%CI: 0.87–0.91) had 
colonoscopy referral and 44% (n=539/1,229; 95%CI: 0.41–0.47) had colonoscopy completion. 
Across FQHCs, range for colonoscopy referral was 73–96% and completion was 18–57%. Six of 
eight (75%) FQHCs reported FIT brands with limited data to support effectiveness.
Conclusions: In a sample of Southern California FQHCs, diagnostic colonoscopy completion 
after abnormal FIT was substantially below the nationally recommended benchmark to achieve 
80% completion, and use of FIT brands with limited data to support effectiveness was high. These 
findings suggest a need for policies and multi-level interventions to promote diagnostic 
colonoscopy among individuals with abnormal FIT, and use of higher quality FITs.
Precis:
In a survey of 8 Federally Qualified Health Centers, among 1,229 patients with an abnormal fecal 
immunochemical test for colorectal cancer screening, 89% had referral, but just 44% completed 
diagnostic colonoscopy, with range of completion ranging 18 to 57% across health centers. The 
findings suggest a major need for policies and multi-level interventions to promote diagnostic 
colonoscopy among patients with abnormal colorectal cancer screening tests.
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Background and Significance
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States (1). 
Screening for CRC can reduce cancer incidence and mortality, but is underutilized. The 
national screening rate in 2015 was 62.6% (2). Screening rates are particularly low for 
racial/ethnic minorities (61.8% for Blacks , 49.9% for Hispanics and 54.3% for American 
Indian/Alaska Natives) (2), those covered by Medicaid (47%) and the uninsured (24.8%) (3). 
Federally Qualified Health Centers (FQHCs), the largest providers of care to under and 
uninsured individuals across the nation, are in a unique position to improve screening rates 
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among disadvantaged, under and uninsured groups with low screening rates. Since 2012, 
FQHCs have been required to publically report rates of CRC screening as part of the Health 
and Human Services required Universal Data Set (UDS: https://bphc.hrsa.gov/uds/
datacenter.), and many, with support from groups such as the NCCRT, have focused on 
improving screening rates. The most current UDS data from 2017 report an aggregate rate of 
CRC screening of 42% across FQHCs nationally.
For many FQHCs, CRC screening efforts focus on promoting uptake of the fecal 
immunochemical test (FIT), because of its low cost, convenience, and accessibility. Beyond 
ensuring test uptake, FQHCs implementing FIT-based screening face two additional key 
challenges to reducing the burden of CRC for their populations. First, effectiveness of FIT-
based screening depends on high rates of diagnostic colonoscopy follow up after abnormal 
FIT. Between one in 11 and one in 28 individuals with an abnormal FIT have CRC, and 
between one in three and one in seven individuals have advanced neoplasia (4–8). As such, 
low rates of colonoscopy follow up after abnormal tests can blunt effectiveness of FIT-based 
programs. Compared to healthcare settings with integrated resources for specialty care, 
FQHCs face unique challenges to identify and coordinate care with outside specialty 
colonoscopy providers that function in separate healthcare systems. Few prior studies have 
evaluated rates of colonoscopy follow up in FQHC settings, and most were either single 
center or included just a few centers (9, 10). Second, effectiveness of FIT based programs 
depends on the brand of FIT selected for implementation. In its last major evidence review 
of CRC screening the United States Preventive Services Task force (USPSTF) concluded 
that sensitivity to detect CRC and high-risk adenomas varies widely across stool-based tests 
that have been approved by the Food and Drug Administration (FDA). Though many brands 
of FIT were evaluated, the USPSTF evidence review identified only two FIT brands [OC-
Light and OC FIT-CHEK (marketed as OC-Sensor Diana, OC-Micro, and OC-Auto)] with 
adequate data to support high sensitivity and specificity. It is unclear which FITs or other 
stool tests FQHCs are choosing, and how often tests with low sensitivity/specificity are used.
Currently, FQHCs are not required to report colonoscopy completion rates after abnormal 
FIT, or type of FIT implemented. Understanding current rates of follow up, and whether 
high quality FITs are being implemented, could inform policies and research focused on 
optimizing outcomes of CRC screening, particularly for underserved populations. 
Accordingly, our goal was to characterize rates of diagnostic colonoscopy referral after 
abnormal FIT, rates of completion of diagnostic colonoscopy after positive FIT, and brand of 
FITs used across a sample of FQHCs in Southern California.
Methods
Study Design and Population
This was a cross-sectional study conducted between January 2015 and June 2016 at eight 
FQHCs in San Diego, Imperial, and Los Angeles counties of California.
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Recruitment of FQHCs
Three study investigators (SG, JN, FPM) sent a letter (Appendix A) to quality improvement 
(QI) personnel in FQHCs in the San Diego, Imperial, and Los Angeles counties. FQHCs 
were identified via targeted recruitment, and American Cancer Society workshops designed 
to train local FQHCs about CRC screening strategies. The FQHCs contacted were informed 
of the importance of diagnostic colonoscopy after abnormal FIT and invited to participate in 
a study to understand rates of colonoscopy completion after abnormal FIT in Southern 
California. Each clinic was offered a $400 honorarium for their participation.
Data Collection
We provided each FQHC with a brief questionnaire, data collection form, and detailed 
instructions on how to define a cohort of patients with abnormal FIT (Appendix A). We 
requested each FQHC create a patient cohort including patients with an abnormal FIT during 
6-month block periods between January 2015 and June 2016. Depending on the size of the 
population served by each FQHC, data were collected in one to three block periods to 
achieve a sample of at least 150 patients with abnormal FIT per site. Each clinic used the 
data collection form to perform either a manual chart review or electronic medical record 
query to abstract patient-level data for gender, medical insurance status, presence of a 
colonoscopy referral after abnormal FIT, and documentation of a completed colonoscopy 
after abnormal FIT. No further data were requested in an effort to maximize participation by 
FQHCs. In the questionnaire, FQHCs provided summative information about patient 
demographics, brand of FIT kit used in their clinics, and colonoscopy referral rates. 
Colonoscopy completion rates were determined from information in the data collection 
form. These aggregated, de-identified data were sent to the study PI at University of 
California San Diego (SG). The study was reviewed by the UC San Diego Human Research 
Protection Program and deemed exempt from further review due to use of de-identified 
aggregate data for analyses.
FQHC Health Resources and Services Administration (HRSA) Data
To gain details about the clinics represented in our sample, we collected demographic data 
on the FQHC sites from HRSA. These data (2015) are collected and made publically 
available (https://bphc.hrsa.gov/uds/datacenter). We merged clinic-level data with the 
primary data collected as part of this study.
Statistical Analyses
Outcomes—The primary outcome was the proportion of individuals with abnormal FIT 
with documented colonoscopy within six months of the test result. Secondary outcomes of 
interest were the proportion of patients with a colonoscopy referral within six months of the 
abnormal FIT, and brands of FIT used at the FQHCs.
Sample size—We estimated (a priori) that we would need a minimum of 150 patient 
participants to achieve 90% confidence that our calculated rate for diagnostic colonoscopy 
after positive FIT reflected the true population rate. This was based on the assumption that 
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any given health center has approximately 300 abnormal test results over a 12-month time 
period.
Analyses—Descriptive statistics were used to characterize the study overall and by clinic 
study population and variation in FIT kit brand. We also calculated rates for colonoscopy 
referral and colonoscopy completion after abnormal FIT for each FQHC and across all 
FQHCs. We computed 95% confidence intervals estimates for all proportions.
Results
FQHC Sample
Of the 20 health centers invited, eight FQHCs agreed to participate in the study and 
contributed data for 1,229 patients (Figure 1). Among non-participants, eight FQHCs cited 
lack of resources (funding and staff time) as the main barriers to participation. The 
remaining FQHCs did not respond to the invitation in a timely manner. The number of 
patients seen annually in each participating FQHC ranged from 55,000 to 135,000 
individuals based on UDS data (Table 1). As is shown in Table 1, nearly all patients served 
by the eight FQHCs were at or below 200% of the Federal Poverty Level. The proportion of 
uninsured ranged from 20 to 45%, while the proportion covered by MediCal (Medicaid) 
ranged from 34 to 72%. Across all clinics, range of patients who were identified as 
Hispanic/Latino was 52 to 94%. UDS CRC screening rates across the 8 FQHCs during the 
study timeframe ranged from 28% to 49% (mean=42%).
Study Population
The eight participating FQHCs contributed data for 1,229 individuals with abnormal FIT 
(Table 2). Each FQHC contributed between 75 and 251 patients. Males comprised 46% of 
the sample; the range for gender was 34% to 54% across sites. Twenty percent (n=244) were 
uninsured, ranging from 11% to 40% across sites.
Referral for Diagnostic Colonoscopy and Colonoscopy Completion After Abnormal FIT
Among 1,229 patients with abnormal FIT, 89% (n=1,091/1,229 95% CI: 0.87–0.91) had 
documented colonoscopy referral and 44% (n=539/1,229 95% CI: 0.41–0.47) had 
documentation of colonoscopy completion (Figure 1). Across FQHCs, the range of 
colonoscopy referral was 73–96%, and the range of colonoscopy completion was 18–57% 
(Figure 2).
FIT Brand
There were several brands of FIT kits represented in the eight FQHCs: Hemosure (n=3), 
Polymedco-OC Auto (n=2), and both Polymedco-OC Auto and Insure (n=3). Clinics 
offering more than one test did so to accommodate insurance coverage. Among these tests, 
only Polymedco-OC Auto is recognized by USPSTF as having sufficient evidence to support 
use. Thus, six out of eight (75%) FQHCs were utilizing FITs with questionable data to 
support effectiveness.
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Discussion
In a sample of eight FQHCs that serve three Southern California counties, we found high 
rates of colonoscopy referral but low completion rates after abnormal FIT, and use of FIT 
brands with uncertain effectiveness for screening. Specifically, 1 in 2 individuals with 
abnormal FIT did not have evidence of colonoscopy completion within 6 months, despite 
colonoscopy referral rates approaching 90% in this study. The public health implications are 
significant, since up to 1 in 10 of the 1,229 individuals with an abnormal FIT who did not 
complete colonoscopy in this sample are expected to have undiagnosed CRC, and failure to 
complete colonoscopy is expected to result in a 2.4 fold increased risk of CRC mortality (4). 
In our sample, additionally, 75% of FQHCs reported using FIT brands not recognized by the 
USPSTF as having sufficient evidence to support use.
These results confirm and extend prior work examining colonoscopy follow up after 
abnormal stool-based screening (11–15). A retrospective study in 2016, also performed in a 
safety-net setting, found that only half of individuals with a positive FIT completed their 
colonoscopy within a year (15). Additional studies in similar settings have identified follow-
up colonoscopy rates between 42 and 68% (14). In these cohorts, barriers to colonoscopy 
completion included increasing age, Hispanic ethnicity, female gender, and high comorbidity 
(11, 12, 14, 15). To our knowledge, our sample describing colonoscopy referral and 
completion rates includes the largest number of distinct FQHCs to date. In addition, our 
study provides the first analysis of FIT brands used in usual practice in this setting.
Our observation that many FQHCs use FIT brands of uncertain effectiveness requires further 
study. Use of suboptimal quality FITs may blunt impact of screening efforts, and also strain 
resources. For example, implementation of tests with suboptimal sensitivity may reduce 
cancer detection, while implementation of tests with suboptimal specificity may lead to 
higher rates of false positive tests, challenging diagnostic colonoscopy capacity and 
burdening patients with recommendations for potentially unnecessary evaluations.
Taken together with prior work, our results have several implications. From a policy 
standpoint, the proportion of patients with abnormal non-invasive tests completing 
diagnostic colonoscopy should be considered as a new, required quality metric. Low rates of 
diagnostic colonoscopy follow up have the potential to greatly compromise efforts to reduce 
CRC incidence and mortality, particularly because failure to complete diagnostic 
colonoscopy after abnormal FIT has been associated with increased risk for CRC death (4). 
A colonoscopy completion metric may be especially salient, given the expanding number of 
alternative tests to colonoscopy being made available in practice (though not universally 
implemented across practice settings), including the FIT-multi target DNA stool test, CT 
colonography, capsule colonoscopy, and the serum septin 9 blood test. A novel abnormal test 
follow up metric would likely be most powerful if required of both health systems (such as 
for FQHCs through inclusion as part of UDS reporting), and insurers (such as through 
Medicaid policies or inclusion as part of the Healthcare Effectiveness Data Information Set). 
From a clinical care and research standpoint, more work to understand reasons for 
colonoscopy non-completion, as well as to develop and implement interventions to improve 
colonoscopy follow up is needed. Potential reasons for failure to complete colonoscopy after 
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stool-based testing include difficulty with bowel preparation, transportation, worry about 
exacerbating existing conditions, concerns about potential complications, and insurance 
status and language barriers (16–18). There is also evidence that organizational challenges in 
care coordination between FQHCs and outside specialty providers hinder care delivery for 
safety-net patients with cancer (19, 20). A limitation of prior work is a lack of data on 
patient reported reasons for failure to follow up.
Interventions to improve rates of colonoscopy follow up include use of patient navigators, 
provider reminders and/or performance data reports, automated referral to gastroenterology, 
and multicomponent QI efforts (21). However, very few interventions have been 
implemented specifically for follow up of abnormal stool blood tests in safety-net settings. 
Future research should seek to expand our knowledge of reasons for failure to follow up and 
develop optimized interventions for colonoscopy completion. The importance of the 
implementation and dissemination of such efforts within FQHCs is magnified by the fact 
that FQHCs serve disproportionately poor and underserved populations with the highest 
burden from CRC. Based on our findings that USPSTF recommended FIT brands is 
infrequent, additional studies should be conducted to verify effectiveness of FITs currently 
approved by the FDA. Further, a larger survey across multiple healthcare settings may be 
needed to understand the frequency with which FITs with limited evidence are in use. 
Education efforts should raise awareness about the differences between FIT brands among 
health systems and providers to support selection of tests with optimal screening test 
characteristics.
Several limitations must be considered in interpreting our results. Because we aimed to 
evaluate FIT follow-up rates in FQHCs in Southern California, our findings may not be 
generalizable to non-FQHC settings or to FQHCs in other regions of the country. In 
addition, only 8 out of 20 FQHCs agreed to participate in the study and our findings may not 
be representative of all FQHCs in San Diego, Imperial, and Los Angeles counties. The 
FQHCs that did not participate commonly cited lack of budget/resources and time for data 
collection. Another limitation is that because only clinic level aggregate data were used, we 
cannot comment on individual barriers to colonoscopy completion. Colonoscopy exposure 
could have been under-ascertained due to factors such as use of a 6 month time window to 
ascertain exposure, or inconsistencies in return of reports from completed colonoscopies to 
the health centers. The 6 month time period was chosen as a practical measure and because 6 
months has been recommended as the maximum allowable time to complete colonoscopy 
within which outcomes may not be affected.(22) To minimize burden of data collection on 
FQHCs and maximize likelihood of participation, only a limited scope of data were 
requested from health centers, precluding ability to conduct patient level analyses of 
predictors of colonoscopy completion. Because additional patient and system level data were 
not collected, we were unable to explore in depth systematic factors (e.g. referral processes) 
and barriers that may have contributed to low rates of follow up and variation in completion 
across health centers, or report on rates of CRC and advanced neoplasia detection. We 
defined high quality FIT brands as those recommended for use in 2016 by the USPSTF 
based on its evidence review. Since the 2016 publication, new comparative FIT data have 
been published, including one study suggesting that the InSure FIT brand has higher 
sensitivity than OC-FIT CHEK, albeit when InSure is used as a 2-sample test compared to 
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OC-FIT CHEK as a 1-sample test (Appendix B) (23). In our data, three FQHCs reported 
using the InSure FIT, suggesting that up to three out of eight (instead of two out of eight) 
were using FITs with sufficient data to support use. Even taking into account this 
adjustment, use of a FIT brand with weak evidence was common (62.5% of FQHCs). These 
limitations may be considered in light of our ability to recruit the largest sample of FQHCs 
reported to assess diagnostic colonoscopy follow up rates, as well as our novel measurement 
of types of FIT implemented.
In summary, among a sample of FQHCs in Southern California, we found that fewer than 1 
in 2 patients with abnormal FIT had evidence of colonoscopy completion, thus placing them 
at markedly increased risk for CRC mortality (4). Further, 6 out of 8 FQHCs were 
implementing FITs not endorsed by the USPSTF for population screening. To realize the full 
potential benefits of CRC screening across the population, health policies, research, and 
interventions are required to optimize high quality screening, including high rates of 
colonoscopy follow up after abnormal FIT, and implementation of high quality FITs.
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Figure 1: Study flow and overall summary of colonoscopy referral and completion in a sample of 
Federally Qualified Health Centers in San Diego, Imperial and Los Angeles Counties of 
California; Jan 2015-June 2016; N= 1229.
The process for sample selection, and overall summary rate of colonoscopy referral and 
completion at included Federally Qualified Health Centers is depicted.
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Figure 2: Diagnostic colonoscopy referral and completion rates after abnormal FIT across a 
sample of 8 Federally Qualified Health Centers in San Diego, Imperial and Los Angeles Counties 
of California; Jan 2015-June 2016; N= 1229.
Proportion of patients with abnormal FIT with colonoscopy referral and colonoscopy 
completion are depicted for each included FQHC. FIT, fecal immunochemical test; FQHC, 
Federally Qualified Health Center.
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Table 1:
Demographic characteristics of individuals served by included Federally Qualified Health Centers in San 
Diego, Imperial and Los Angeles Counties of California 2015 (n=8)
FQHC 1 FQHC 2 FQHC 3 FQHC 4 FQHC 5 FQHC 6 FQHC 7 FQHC 8
Total Patients Served 89,662 134,788 55,465 64,834 23,119 17,214 19,415 85,860
 Adult (18 – 64) 55% 70% 63% 64% 68% 89% 64% 53%
 Older Adults (≥ 65) 9% 5% 4% 5% 5% 6% 5% 3%
Patients ≤ 200% of poverty 97% 97% 98% 98% 97% 97% 99% 98%
Patients ≤ 100% of poverty 79% 81% 79% 80% 75% 73% 90% 82%
Insurance Status
 Uninsured 31% 30% 31% 20% 22% 39% 45% 28%
 Medicaid/CHIP 57% 62% 58% 72% 69% 34% 47% 66%
 Medicare 8% 4% 2% 6% 5% 3% 3% 3%
 Other Third Party 4% 4% 8% 2% 5% 24% 4% 4%
Ethnicity
 Hispanic/Latino 81% 59% 62% 53% 57% 52% 94% 75%
 Non-Hispanic/ Latino 19% 41% 38% 47% 43% 48% 6% 25%
Race*
 White 46% 77% 91% 90% 85% 77% 95% 89%
 Black/African American 28% 12% 3% 3% 11% 15% 4% 9%
 Asian 21% 5% 2% 4% 4% 8% 0. 1% 2%
 American Indian/Alaska Native 2% 1% 0. 2% 0. 4% 0. 2% 0. 2% 0. 0% 0. 4%
 Native Hawaiian / Other Pacific 
Islander 2% 1% 1% 0% 0% 0% 0% 0. 2%
 More than one race 1% 4% 3% 3% 0. 2% 0. 2% 1% 0. 1%
Patients age 50–75 years Up-to-Date with 
colorectal cancer screening 43% 34% 28% 46% 43% 45% 45% 49%
Source: Publically reported United States Health and Human Services data at https://bphc.hrsa.gov/uds/datacenter; Percentages have been rounded 
to the nearest numbers;
*due to rounding, percentages do not sum to 100% for all clinics
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Table 2:
Demographic characteristics of individuals with abnormal FIT at Federally Qualified Health Centers in San 
Diego, Imperial and Los Angeles Counties of California; Jan 2015-June 2016; N= 1229
Health Centers Male n (%) Uninsured n (%)
Overall N=1229 559 (46%) 244 (20%)
FQHC 1 (n=150) 81 (54%) 16 (11%)
FQHC 2 (n=150) 73 (49%) 35 (23%)
FQHC 3 (n=188) 89 (47%) 27 (14%)
FQHC 4 (n=251) 128 (51%) 28 (11%)
FQHC 5 (n=150) 63 (42%) 32 (21%)
FQHC 6 (n=75) 26 (35%) 30 (40%)
FQHC 7 (n=150) 51 (34%) 35 (23%)
FQHC 8 (n=115) 48 (42%) 41 (36%)
Source: Survey of health center utilized for study
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